| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg at last 2 consecutive visits of placebo run‐in, with difference between visits of 10 mm Hg or less; 12‐week double‐blind treatment |
| Participants |
Moexipril 7.5 mg: n=51(31 males,20 females); mean age=54.9 years; baseline sitting SBP=152.2 mm Hg, DBP=101.8 mm Hg, HR=75.8 bpm; baseline standing SBP=148.4 mm Hg, DBP=100.9 mm Hg;
Moexipril 15 mg: n=47(30 males,17 females); mean age=56.0 years; baseline sitting SBP=154.0 mm Hg, DBP=100.9 mm Hg, HR=73.6 bpm; baseline standing SBP=150.4 mm Hg, DBP=100.2 mm Hg;
Placebo: n=51(37 males,14 females); mean age=55.3 years; baseline sitting SBP=154.2 mm Hg, DBP=101.2 mm Hg, HR=74.7 bpm; baseline standing SBP=150.9 mm Hg, DBP=101.1 mm Hg |
| Interventions |
Moexipril 7.5 mg once daily;
Moexipril 15 mg once daily;
Placebo |
| Outcomes |
Adjusted mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Trough sitting DBP using mercury sphygmomanometer;
Trough standing SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change reported; endpoint SBP not reported, endpoint DBP reported, endpoint SD not reported; change in SBP data from Table 3, p. 85; change in DBP data from Table 2, p. 83; Jadad score=3; funding source= Schwarz Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
